Literature DB >> 20065495

Experimental and simulation studies on the mechanisms of levetiracetam-mediated inhibition of delayed-rectifier potassium current (KV3.1): contribution to the firing of action potentials.

C W Huang1, J J Tsai, C C Huang, S N Wu.   

Abstract

Levetiracetam (LEV) is an S-enantiomer pyrrolidone derivative with established antiepileptic efficacy in generalized epilepsy and partial epilepsy. However, its effects on ion currents and membrane potential remain largely unclear. We investigated the effect of LEV on differentiated NG108-15 neurons. In these cells treated with dibutyryl cyclic AMP, the expression level of the K(V)3.1 mRNA was elevated. With the aid of patch clamp technology, we found that LEV could suppress the amplitude of delayed rectifier K(+) current (I(K(DR))) in a concentration-dependent manner with an IC(50) value of 37 microM. LEV (30 microM) shifted the steady-state activation of I(K(DR)) to a more positive potential by 10 mV, without shifting the steady-state inactivation of I(K(DR)). Neither Na(+), nor erg (ether-a-go-go-related)-mediated K(+) and ATP-sensitive K(+) currents were affected by LEV (100 microM). LEV increased the duration of action potentials in current clamp configuration. Simulation studies in a modified Hodgkin-Huxley neuron and network unraveled that the reduction of slowly inactivating I(K(DR)) resulted in membrane depolarization accompanied by termination of the firing of action potentials in a stochastic manner. Therefore, the inhibitory effects on slowly inactivating I(K(DR)) (K(V)3.1-encoded current) may constitute one of the underlying mechanisms through which LEV affect neuronal activity in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20065495

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  7 in total

1.  Combined administration of levetiracetam and valproic acid attenuates age-related hyperactivity of CA3 place cells, reduces place field area, and increases spatial information content in aged rat hippocampus.

Authors:  Jonathan Robitsek; Marcia H Ratner; Tara Stewart; Howard Eichenbaum; David H Farb
Journal:  Hippocampus       Date:  2015-07-14       Impact factor: 3.899

2.  Effects of phenobarbital and levetiracetam on PR and QTc intervals in patients with post-stroke seizure.

Authors:  Antonio Siniscalchi; Francesco Scaglione; Enzo Sanzaro; Francesco Iemolo; Giorgio Albertini; Gianluca Quirino; Maria Teresa Manes; Santo Gratteri; Nicola Biagio Mercuri; Giovambattista De Sarro; Luca Gallelli
Journal:  Clin Drug Investig       Date:  2014-12       Impact factor: 2.859

3.  Effect of valproate, lamotrigine and levetiracetam on excitability and firing properties of CA1 neurons in rat brain slices.

Authors:  Marita Englund; Lars Hyllienmark; Tom Brismar
Journal:  Cell Mol Neurobiol       Date:  2011-02-19       Impact factor: 5.046

Review 4.  Connectivity concepts in neuronal network modeling.

Authors:  Johanna Senk; Birgit Kriener; Mikael Djurfeldt; Nicole Voges; Han-Jia Jiang; Lisa Schüttler; Gabriele Gramelsberger; Markus Diesmann; Hans E Plesser; Sacha J van Albada
Journal:  PLoS Comput Biol       Date:  2022-09-08       Impact factor: 4.779

Review 5.  Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy.

Authors:  Sima I Patel; Angela K Birnbaum; James C Cloyd; Ilo E Leppik
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

6.  Does Levetiracetam Administration Prevent Cardiac Damage in Adulthood Rats Following Neonatal Hypoxia/Ischemia-Induced Brain Injury?

Authors:  Serkan Gurgul; Belgin Buyukakilli; Mustafa Komur; Cetin Okuyaz; Ebru Balli; Tuba Ozcan
Journal:  Medicina (Kaunas)       Date:  2018-04-10       Impact factor: 2.430

7.  The Novel Direct Modulatory Effects of Perampanel, an Antagonist of AMPA Receptors, on Voltage-Gated Sodium and M-type Potassium Currents.

Authors:  Ming-Chi Lai; Ray-Chang Tzeng; Chin-Wei Huang; Sheng-Nan Wu
Journal:  Biomolecules       Date:  2019-10-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.